This analysis evaluates the cost-effectiveness (C/E) of routine vaccination against Neisseria meningitidis. Three different preventive strategies are analyzed: mass vaccination during epidemics (the current standard of care), routine preventive vaccination and a combination strategy of routine vaccination with mass vaccination during epidemics. A Markov model is used to simulate the epidemics of meningitis in a cohort of 5-year old children and compare these different strategies. The results show that mass vaccination strategy is dominated by the two other strategies. The incremental C/E ratios are US$50/QALY for the routine vaccination, and US$199/QALY for the combination strategy. The costs per fatal case averted are US$1161 for the routi...
The optimal long-term vaccination strategies to provide population-level protection against serogrou...
Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...
© 2015 Taylor & Francis Group, LLC. NmenB vaccine (4CMenB) is now available, but studies on the cost...
Neisseria meningitidis constitutes a major public health problem among countries in the African meni...
Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaig...
Background: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has drama...
BACKGROUND:The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramat...
Background. Despite the introduction of an effective serogroup A conjugate vaccine (MenAfriVac™), sp...
This paper presents a deterministic model for Neisseria meningitidis, a bacterium that causes mening...
Objective: The optimal long-term vaccination strategies to provide population-level protection again...
The optimal long-term vaccination strategies to provide population-level protection against serogrou...
<div><p>Objective</p><p>The optimal long-term vaccination strategies to provide population-level pro...
Background: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was intro...
BACKGROUND: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was intro...
Abstract Background Meningococcal meningitis is a major cause of disease worldwide, with frequent ep...
The optimal long-term vaccination strategies to provide population-level protection against serogrou...
Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...
© 2015 Taylor & Francis Group, LLC. NmenB vaccine (4CMenB) is now available, but studies on the cost...
Neisseria meningitidis constitutes a major public health problem among countries in the African meni...
Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaig...
Background: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has drama...
BACKGROUND:The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramat...
Background. Despite the introduction of an effective serogroup A conjugate vaccine (MenAfriVac™), sp...
This paper presents a deterministic model for Neisseria meningitidis, a bacterium that causes mening...
Objective: The optimal long-term vaccination strategies to provide population-level protection again...
The optimal long-term vaccination strategies to provide population-level protection against serogrou...
<div><p>Objective</p><p>The optimal long-term vaccination strategies to provide population-level pro...
Background: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was intro...
BACKGROUND: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was intro...
Abstract Background Meningococcal meningitis is a major cause of disease worldwide, with frequent ep...
The optimal long-term vaccination strategies to provide population-level protection against serogrou...
Control of meningitis epidemics is based on early case detection followed by mass campaigns of immun...
© 2015 Taylor & Francis Group, LLC. NmenB vaccine (4CMenB) is now available, but studies on the cost...